Please login to the form below

Ashfield announces leadership changes in the U.S. and Japan.

Ashfield announces the appointment of Greg Flynn as Regional President of Commercial and Clinical in the U.S. and Mick O’Leary as Regional President of Commercial and Clinical in Japan, where he will lead CMIC Ashfield.

Greg Flynn will oversee U.S. operations of Commercial, Clinical, Medical Information, Pharmacovigilance and Market Access. Greg is transitioning to this role from his prior position as Regional President in Japan and Representative Director of CMIC Ashfield, a joint initiative between CMIC Holdings Co., Ltd and UDG Healthcare plc. Under Greg’s leadership, Ashfield became an industry leading partner with over 650 staff across 44 clients in five years.



Mick O’Leary will take over the role as Regional President in Japan, leading the CMIC Ashfield joint venture. Mick was previously the Managing Director for Ashfield Ireland, and has over 20 years’ experience in the pharmaceutical sales industry. Under Mick’s leadership, Ashfield has been established as the Number 1 CSO in Ireland with over 60% market share.



Commenting on his appointment, Greg Flynn said: “Through the talent of our people and Ashfield’s commitment to helping improve lives, I have seen the power of what we do in this organisation. The U.S. business has experienced phenomenal growth in the last two years and this new role is an exciting opportunity to continue that growth. I am excited about the future of Ashfield in the U.S. and being part of the next phase in this company’s journey.”

Mick O’Leary commented, “I am delighted to accept the role of Regional President in Japan and support the group’s overall strategy of expansion in growth markets. CMIC Ashfield is a winning proposition, combining the experience and expertise of a leading international CSO, with the local knowledge and capability of one of Japan’s leading CSOs. We’ll continue to excel by providing flexible, evidence-based services and I look forward to working with new clients and brand challenges in Japan.”

Julian Tompkins, Global President for Ashfield Clinical and Commercial business also commented: “We are delighted to have appointed these critical roles for the business. Greg’s leadership in the Japanese market has yielded remarkable growth and proven his dedication to Ashfield’s success. With Greg’s innovative thinking and focus on people, we are looking forward to seeing his impact on the U.S. business.

The appointment of Mick O’Leary as Regional President in Japan will continue our success story and excellent results in the second largest global pharmaceutical market. He has exactly the right expertise and drive to lead CMIC Ashfield and continue our strong progress in Japan.”

For more information on Ashfield services visit ashfieldhealthcare.com or for questions on this article contact jane.neale@ashfieldhealthcare.com.


15th June 2017

Share

Company Details

Ashfield

Contact Website

Address:
Ashfield House
Resolution Road
Ashby de la Zouch
Leicestershire
LE65 1HW
UK

Latest content on this profile

‘Delivering healthcare events with certainty and impact’
Ashfield Meetings & Events launches new website Ashfieldmeetings.com
Ashfield
The Ashfield Solution - Accelerate product uptake and maximize ROI
A pioneering multichannel optimization model powered by advanced analytics with the ability to flex resources based on real time results.
Ashfield
Patient Engagement and Experience Conference, 16-17 May
Ashfield and S3 Connected Health, Silver Sponsors at the 3rd Annual Patient Engagement and Experience Conference in Amsterdam on 16-17 May, will be speaking on how digitally enhanced Patient Support Programmes can extend the continuity and relevance of care into patients’ everyday lives.
Ashfield
Ashfield will be exhibiting at ISMPP US
On 30 April - 2 May 2018, Ashfield Healthcare Communications will be exhibiting at the 14th Annual Meeting of ISMPP at the Gaylord National Resort & Convention Center, National Harbor, MD.
Ashfield
Putting the patient first
You’ve invested millions in the development of your new drug or therapy and have successfully completed clinical trials - now you are ready to launch. Data has been collected, efficacy is understood and side effects are recorded. But an important question remains: is your target patient population prepared?
Ashfield
Ashfield joins the eyeforpharma webinar: The PSP Masterclass
Nagore Fernandez, Ashfield’s Head of Patient Services for EUCAN and Anna Baker, a Consultant in Health Psychology working closely with Ashfield, are joining an eyeforpharma panel debate: 'How Health Psychology drives winning Patient Support Programmes'. The webinar will take place Thursday 26th April at 9am New York, 2pm UK and 3pm Paris time.
Ashfield